Checkpoint Kinase Inhibitor Pipeline Analysis

Checkpoint Kinase Inhibitor Pipeline Analysis \"Checkpoint Kinase Inhibitor Pipeline\" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Checkpoint Kinase Inhibitor pipeline landscape is provided, which includes the topic overview and Checkpoint Kinase Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Checkpoint Kinase Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product- related details. What are Checkpoint Kinases? The development of Checkpoint Kinase Inhibitors to treat cancer has been a major objective in drug discovery. Checkpoint Kinases are protein kinases, Chk1 and Chk2, Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell- cycle progression in the presence of DNA damage. Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. Which are the key players involved in development of Checkpoint Kinase Inhibitor Pipeline drugs?

Key Players involved in Checkpoint Kinase Inhibitor Pipeline are Boehringer Ingelheim, CanBas, Vernalis, Sierra Oncology, Pharos I&BT Co, Eli Lilly and company, Sentinel Oncology, IMPACT Therapeutics, Pink Biopharma, and others. Which are Checkpoint Kinase Inhibitor Pipeline Drugs? Drug Company Clinical Phase RoA SRA737 Sierra Oncology I/II Oral CBP501 CanBas I Intravenous PHI 101 Pharos I&BT I Oral BI 765063 Boehringer Ingelheim I Parenteral Prexasertib Eli Lilly and Company I NA SOL-578 Sentinel Oncology Preclinical NA V158411 Vernalis Preclinical Intravenous Research Programme: Pink Biopharma Discovery NA Checkpoint Kinase Inhibitors IMP 10 IMPACT Therapeutics Discovery NA Scope of the report  The Checkpoint Kinase Inhibitor report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.  It comprises of detailed profiles of Checkpoint Kinase Inhibitor therapeutic products with key coverage of involved technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.  Elucidated Checkpoint Kinase Inhibitor research and development progress and trial details, results wherever available, are also included in the pipeline study.  Coverage of dormant and discontinued pipeline projects along with the reasons if available across Checkpoint Kinase Inhibitor.

For more information on Checkpoint Kinase Inhibitors, visit Checkpoint Kinase Inhibitor Pipeline Analysis